2022
State insurance mandates for in vitro fertilization are not associated with improving racial and ethnic disparities in utilization and treatment outcomes
Correia K, Kraschel K, Seifer D. State insurance mandates for in vitro fertilization are not associated with improving racial and ethnic disparities in utilization and treatment outcomes. American Journal Of Obstetrics And Gynecology 2022, 228: 313.e1-313.e8. PMID: 36356698, DOI: 10.1016/j.ajog.2022.10.043.Peer-Reviewed Original ResearchConceptsNon-Hispanic white womenClinical outcomesEthnic disparitiesFertilization cyclesFertility careAssisted Reproductive Technology Clinical Outcomes Reporting SystemBlack/African American womenWhite womenSingle stimulation cycleInsurance mandatesReproductive-aged womenRecent study yearsLack of insuranceAfrican American womenAutologous cyclesLiveborn neonatesCohort studyPrimary outcomeState insurance mandatesState health insurance mandatesStimulation cyclesTreatment outcomesWomenHealth insurance mandatesOutcomes
2018
Temporal Differences in Utilization of Intracytoplasmic Sperm Injection Among U.S. Regions
Zagadailov P, Hsu A, Stern JE, Seifer DB. Temporal Differences in Utilization of Intracytoplasmic Sperm Injection Among U.S. Regions. Obstetrics And Gynecology 2018, 132: 310-320. PMID: 29995722, DOI: 10.1097/aog.0000000000002730.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAge FactorsCohort StudiesFemaleFertilization in VitroHumansInfertility, FemaleInfertility, MaleLive BirthMalePregnancyPregnancy RateRetrospective StudiesSperm Injections, IntracytoplasmicTreatment OutcomeUnited StatesUnited States Dept. of Health and Human ServicesYoung AdultConceptsLive birth rateUse of ICSIICSI rateICSI utilizationBirth rateRetrospective cohort studyMale factor infertilityHuman Services (HHS) regionsIntracytoplasmic sperm injectionYears of agePreimplantation genetic testingMale factor diagnosisDepartment of HealthNondonor cyclesCohort studyFertilization cyclesFactor infertilityMale factorSperm injectionMedical indicationsMagnitude of increaseClinicGenetic testingDisease controlICSIAntimüllerian hormone as a predictor of live birth following assisted reproduction: an analysis of 85,062 fresh and thawed cycles from the Society for Assisted Reproductive Technology Clinic Outcome Reporting System database for 2012–2013
Tal R, Seifer DB, Wantman E, Baker V, Tal O. Antimüllerian hormone as a predictor of live birth following assisted reproduction: an analysis of 85,062 fresh and thawed cycles from the Society for Assisted Reproductive Technology Clinic Outcome Reporting System database for 2012–2013. Fertility And Sterility 2018, 109: 258-265. PMID: 29331235, DOI: 10.1016/j.fertnstert.2017.10.021.Peer-Reviewed Original ResearchAdultAnti-Mullerian HormoneArea Under CurveBiomarkersChi-Square DistributionCryopreservationDatabases, FactualEmbryo TransferFemaleFertilization in VitroHumansInfertilityLive BirthLogistic ModelsMaleOdds RatioPregnancyPregnancy RateRetrospective StudiesRisk FactorsROC CurveSingle Embryo TransferTime FactorsTreatment Outcome
2016
Biosimilar FSH preparations- are they identical twins or just siblings?
Orvieto R, Seifer DB. Biosimilar FSH preparations- are they identical twins or just siblings? Reproductive Biology And Endocrinology 2016, 14: 32. PMID: 27301324, PMCID: PMC4908720, DOI: 10.1186/s12958-016-0167-8.Peer-Reviewed Original ResearchMeSH KeywordsBiosimilar PharmaceuticalsFemaleFollicle Stimulating HormoneHumansPregnancyPregnancy RateRecombinant ProteinsTreatment OutcomeConceptsFSH preparationsPregnancy rateClinical practicePhase 3 clinical trialsIncidence of OHSSOngoing pregnancy ratePolycystic ovary syndromeAdditional patient populationsPopulation of womenDose-response curveRecombinant FSH preparationsBiosimilar productsNormal respondersIVF failurePoor respondersOvary syndromeClinical efficacyPatient populationClinical trialsBiosimilar agentsSteelman-PohleyClinical useFurther comparative studiesPatientsIdentical twinsSociety for Assisted Reproductive Technology and assisted reproductive technology in the United States: a 2016 update
Toner JP, Coddington CC, Doody K, Van Voorhis B, Seifer DB, Ball GD, Luke B, Wantman E. Society for Assisted Reproductive Technology and assisted reproductive technology in the United States: a 2016 update. Fertility And Sterility 2016, 106: 541-546. PMID: 27301796, DOI: 10.1016/j.fertnstert.2016.05.026.Peer-Reviewed Original Research
2015
Prognostic indicators of assisted reproduction technology outcomes of cycles with ultralow serum antimüllerian hormone: a multivariate analysis of over 5,000 autologous cycles from the Society for Assisted Reproductive Technology Clinic Outcome Reporting System database for 2012–2013
Seifer DB, Tal O, Wantman E, Edul P, Baker VL. Prognostic indicators of assisted reproduction technology outcomes of cycles with ultralow serum antimüllerian hormone: a multivariate analysis of over 5,000 autologous cycles from the Society for Assisted Reproductive Technology Clinic Outcome Reporting System database for 2012–2013. Fertility And Sterility 2015, 105: 385-393.e3. PMID: 26515380, DOI: 10.1016/j.fertnstert.2015.10.004.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnti-Mullerian HormoneBiomarkersCryopreservationDatabases, FactualEmbryo TransferFemaleFertilityFertilization in VitroHumansInfertilityLinear ModelsLive BirthLogistic ModelsMiddle AgedMultivariate AnalysisOocyte RetrievalPatient SelectionPregnancyPregnancy RatePregnancy, MultipleReproductive Techniques, AssistedRetrospective StudiesRisk AssessmentRisk FactorsTreatment OutcomeYoung AdultConceptsLive birth rateAntimüllerian hormoneCancellation rateAMH levelsAssisted Reproductive Technology Clinic Outcome Reporting System databaseAssisted reproduction technology (ART) outcomesEmbryo cryopreservation ratesSerum antimüllerian hormoneTotal cancellation rateMultiple birth ratesReporting System databaseCycle startAutologous cyclesClinical pregnancyCycle cancellationPrognostic factorsAMH valuesFresh cyclesCycle outcomePrognostic indicatorAMH concentrationsRetrospective analysisMAIN OUTCOMEEmbryo transferMultivariate analysis
2014
Assisted hatching and intracytoplasmic sperm injection are not associated with improved outcomes in assisted reproduction cycles for diminished ovarian reserve: an analysis of cycles in the United States from 2004 to 2011
Butts SF, Owen C, Mainigi M, Senapati S, Seifer DB, Dokras A. Assisted hatching and intracytoplasmic sperm injection are not associated with improved outcomes in assisted reproduction cycles for diminished ovarian reserve: an analysis of cycles in the United States from 2004 to 2011. Fertility And Sterility 2014, 102: 1041-1047.e1. PMID: 25086790, PMCID: PMC4184996, DOI: 10.1016/j.fertnstert.2014.06.043.Peer-Reviewed Original ResearchMeSH KeywordsChi-Square DistributionEmbryo Culture TechniquesEmbryo TransferFemaleHumansInfertility, FemaleLive BirthLogistic ModelsOdds RatioOvarian ReservePregnancyPregnancy RatePrimary Ovarian InsufficiencyRegistriesRetrospective StudiesRisk FactorsSperm Injections, IntracytoplasmicTime FactorsTreatment OutcomeUnited StatesConceptsDiminished ovarian reserveIntracytoplasmic sperm injectionElevated FSHLive birthsOvarian reserveART cyclesSperm injectionAssisted Reproductive Technology Clinic Outcome Reporting System databaseClinical pregnancy rateRetrospective cohort studyLive birth rateReproductive technology outcomesAssisted reproduction cyclesCombination of ICSIReporting System databaseCohort studyPrimary diagnosisImproved outcomesPregnancy rateMAIN OUTCOMELower oddsDiminished oddsFSHOnly indicationTechnology outcomesCharacterization of women with elevated antimüllerian hormone levels (AMH): correlation of AMH with polycystic ovarian syndrome phenotypes and assisted reproductive technology outcomes
Tal R, Seifer DB, Khanimov M, Malter HE, Grazi RV, Leader B. Characterization of women with elevated antimüllerian hormone levels (AMH): correlation of AMH with polycystic ovarian syndrome phenotypes and assisted reproductive technology outcomes. American Journal Of Obstetrics And Gynecology 2014, 211: 59.e1-59.e8. PMID: 24593938, DOI: 10.1016/j.ajog.2014.02.026.Peer-Reviewed Original ResearchConceptsSerum antimüllerian hormone levelsAntimüllerian hormone levelsClinical pregnancy ratePopulation of womenAMH levelsPregnancy rateHormone levelsHigher clinical pregnancy rateElevated AMH levelsPresence of amenorrheaMultiple pregnancy rateOvarian hyperstimulation syndromeRetrospective cohort studyHigher AMH levelsPolycystic ovarian morphologyPolycystic ovarian syndromeSyndrome phenotypeReproductive technology outcomesHyperstimulation syndromePCOS severityClinical pregnancyOvarian stimulationTotal testosteroneCohort studyOvarian syndromeVitamin D Increases Serum Levels of the Soluble Receptor for Advanced Glycation End Products in Women With PCOS
Irani M, Minkoff H, Seifer DB, Merhi Z. Vitamin D Increases Serum Levels of the Soluble Receptor for Advanced Glycation End Products in Women With PCOS. The Journal Of Clinical Endocrinology & Metabolism 2014, 99: e886-e890. PMID: 24606102, DOI: 10.1210/jc.2013-4374.Peer-Reviewed Original ResearchConceptsAdvanced glycation end productsPolycystic ovary syndromeAnti-Mullerian hormoneSerum anti-Mullerian hormoneGlycation end productsVitamin DSerum sRAGED3 supplementationDeficient womenAMH concentrationsVit D3Soluble receptorDeposition of AGEsAbnormal ovarian folliculogenesisDihydroxyvitamin D3 supplementationSerum sRAGE levelsVit D3 supplementationVitamin D supplementationSerum AMH levelsVitamin D deficiencyBody mass indexD supplementationAMH levelsD deficiencySRAGE levels
2011
Random anti-Müllerian hormone (AMH) is a predictor of ovarian response in women with elevated baseline early follicular follicle-stimulating hormone levels
Buyuk E, Seifer DB, Younger J, Grazi RV, Lieman H. Random anti-Müllerian hormone (AMH) is a predictor of ovarian response in women with elevated baseline early follicular follicle-stimulating hormone levels. Fertility And Sterility 2011, 95: 2369-2372. PMID: 21497340, DOI: 10.1016/j.fertnstert.2011.03.071.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnti-Mullerian HormoneBiomarkersChi-Square DistributionEmbryo TransferFemaleFertilization in VitroFollicle Stimulating Hormone, HumanFollicular PhaseHumansInfertility, FemaleNew YorkOocyte RetrievalOvulationOvulation InductionPregnancyPregnancy RateRetrospective StudiesTime FactorsTreatment OutcomeUp-RegulationConceptsAnti-Müllerian hormoneNumber of oocytesClinical pregnancy rateSerum AMH levelsDiminished ovarian reserveAMH levelsFSH levelsDay 3 embryosElevated FSHOvarian responseART cyclesPregnancy rateEarly follicular FSH levelsFollicle-stimulating hormone levelsSerum anti-Müllerian hormoneCycle cancellation rateSerum FSH levelsReproductive technology programCycle cancellationOvarian reserveRetrospective studyHormone levelsMAIN OUTCOMECancellation rateRandom sera
2007
Disparity in assisted reproductive technologies outcomes in black women compared with white women
Seifer DB, Frazier LM, Grainger DA. Disparity in assisted reproductive technologies outcomes in black women compared with white women. Fertility And Sterility 2007, 90: 1701-1710. PMID: 17980873, DOI: 10.1016/j.fertnstert.2007.08.024.Peer-Reviewed Original ResearchMeSH KeywordsAbortion, SpontaneousAdultBlack or African AmericanFemaleHealth Knowledge, Attitudes, PracticeHealthcare DisparitiesHumansInfertilityLive BirthPatient Acceptance of Health CareRegistriesReproductive Techniques, AssistedRetrospective StudiesRisk FactorsTime FactorsTreatment OutcomeUnited StatesWhite PeopleConceptsLive birth rateIVF cyclesWhite womenAssisted Reproductive Technology member clinicsBlack womenMarried reproductive age womenCycles of IVFIndependent risk factorRetrospective cohort studyReproductive technology outcomesReproductive-age womenUterine factor infertilityRace/ethnicityCohort studyFactor infertilityBlack raceRisk factorsSpontaneous abortionRegistry dataLive birthsMAIN OUTCOMEEmbryo cyclesIVF recipientsMember clinicsWomenRelationship of bariatric surgery to Müllerian-inhibiting substance levels
Merhi ZO, Minkoff H, Feldman J, Macura J, Rodriguez C, Seifer DB. Relationship of bariatric surgery to Müllerian-inhibiting substance levels. Fertility And Sterility 2007, 90: 221-224. PMID: 17727846, DOI: 10.1016/j.fertnstert.2007.05.073.Peer-Reviewed Original Research
2005
Müllerian inhibiting substance levels at the time of HCG administration in IVF cycles predict both ovarian reserve and embryo morphology
Silberstein T, MacLaughlin DT, Shai I, Trimarchi JR, Lambert-Messerlian G, Seifer DB, Keefe DL, Blazar AS. Müllerian inhibiting substance levels at the time of HCG administration in IVF cycles predict both ovarian reserve and embryo morphology. Human Reproduction 2005, 21: 159-163. PMID: 16123085, DOI: 10.1093/humrep/dei270.Peer-Reviewed Original ResearchConceptsBasal FSH levelsOvarian reserveFSH levelsHCG administrationMIS levelsIVF outcomesOocyte qualityDay 3 FSH levelsMI levelsImproved oocyte qualityTime of hCGClinical pregnancy rateManagement of patientsSerum estradiol levelsHigher implantation rateEmbryo morphologyEmbryo morphology scoreNumber of oocytesEarly antral folliclesEnzyme-linked immunosorbentIVF cyclesOocyte retrievalPatient ageEstradiol levelsImplantation rate
2004
Serum antimüllerian hormone/müllerian-inhibiting substance appears to be a more discriminatory marker of assisted reproductive technology outcome than follicle-stimulating hormone, inhibin B, or estradiol
Hazout A, Bouchard P, Seifer DB, Aussage P, Junca AM, Cohen-Bacrie P. Serum antimüllerian hormone/müllerian-inhibiting substance appears to be a more discriminatory marker of assisted reproductive technology outcome than follicle-stimulating hormone, inhibin B, or estradiol. Fertility And Sterility 2004, 82: 1323-1329. PMID: 15533354, DOI: 10.1016/j.fertnstert.2004.03.061.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnti-Mullerian HormoneBiomarkersEstradiolFemaleFertilization in VitroFollicle Stimulating HormoneGlycoproteinsHumansInhibinsMultivariate AnalysisOsmolar ConcentrationOvulation InductionPredictive Value of TestsPregnancyPregnancy RateRetrospective StudiesTesticular HormonesTime FactorsTreatment OutcomeConceptsReproductive technology outcomesMullerian-inhibiting substanceYears of ageMultivariate regression analysisInhibin BPregnancy outcomesIVF outcomesAntimullerian hormoneHigher clinical pregnancy rateSerum samplesAvailable serum markersDay 3 FSHSerum antimullerian hormoneClinical pregnancy rateClinical pregnancy outcomesInhibin B levelsFollicle-stimulating hormoneConsecutive serum samplesMüllerian-inhibiting substanceGreater prognostic valueTechnology outcomesRegression analysisClinical pregnancyOvarian stimulationOvulation induction
2000
Inhibin B response to EFORT is associated with the outcome of oocyte retrieval in the subsequent in vitro fertilization cycle
Dzik A, Lambert-Messerlian G, Izzo V, Soares J, Pinotti J, Seifer D. Inhibin B response to EFORT is associated with the outcome of oocyte retrieval in the subsequent in vitro fertilization cycle. Fertility And Sterility 2000, 74: 1114-1117. PMID: 11119736, DOI: 10.1016/s0015-0282(00)01627-7.Peer-Reviewed Original ResearchConceptsInhibin B levelsInhibin B serum levelsB levelsInhibin B responsesSubsequent IVF cycleLevels 24 hoursAcademic clinical practiceGood responsePg/mLGonadotropin challengeBaseline serumInhibin BIVF cyclesOvarian stimulationOocyte retrievalOvarian reserveFertilization cyclesOvarian responseSerum levelsPoor responseOdds ratioMAIN OUTCOMEClinical practiceCorresponding oddsPg/
1994
Reproductive potential after treatment for persistent ectopic pregnancy **Presented in part at the conjoint meeting of The American Fertility Society and the Canadian Fertility and Andrology Society, Montreal, Quebec, Canada, October 11 to 14, 1993.
Seifer D, Silva P, Grainger D, Barber S, Grant W, Gutmann J. Reproductive potential after treatment for persistent ectopic pregnancy **Presented in part at the conjoint meeting of The American Fertility Society and the Canadian Fertility and Andrology Society, Montreal, Quebec, Canada, October 11 to 14, 1993. Fertility And Sterility 1994, 62: 194-196. PMID: 8005291, DOI: 10.1016/s0015-0282(16)56841-1.Peer-Reviewed Original ResearchMeSH KeywordsAdultFemaleHumansMethotrexatePregnancyPregnancy, EctopicReproductionSalpingostomyTime FactorsTreatment OutcomeConceptsContralateral fallopian tubeClinical pregnancy rateFallopian tubePregnancy rateCumulative clinical pregnancy rateIntrauterine pregnancy ratePersistent ectopic pregnancyAmerican Fertility SocietyClinical pregnancyEctopic pregnancyTreatment failureCanadian FertilityAndrology SocietySuccessful treatmentPrimary treatmentFertility SocietyRelative riskReproductive outcomesConjoint MeetingObvious pathologySignificant associationSuccess rateTreatmentPregnancySalpingectomyAberrant estradiol flare despite gonadotropin-releasing hormone-agonist-induced suppression is associated with impaired implantation**Presented at the 48th Annual Meeting of The American Fertility Society, New Orleans, Louisiana, November 2 to 5, 1992.
Penzias A, Lee G, Seifer D, Shamma F, DeCherney A, Reindollar R, Jones E. Aberrant estradiol flare despite gonadotropin-releasing hormone-agonist-induced suppression is associated with impaired implantation**Presented at the 48th Annual Meeting of The American Fertility Society, New Orleans, Louisiana, November 2 to 5, 1992. Fertility And Sterility 1994, 61: 558-560. PMID: 8137986, DOI: 10.1016/s0015-0282(16)56595-9.Peer-Reviewed Original ResearchConceptsAmerican Fertility SocietyBioactive LHDelayed suppressionImpairs implantationOvarian suppressionPituitary suppressionCycle outcomePrognostic markerE2 responseFertility SocietyE2 productionAberrant riseGnRHFurther studiesPrevious reportsRapid suppressionImplantationSuppressionAnnual MeetingLH